Menu
Menu
Hosted by: SOPHiA GENETICS
Presented by: Alexandre Harlé
Professor of of Biopathology, Head of Precision Medicine and Translational Research Service, Institut de Cancérologie de Lorraine (ICL), France
As precision oncology advances, clinicians and researchers require solid tumor profiling tools that go beyond traditional approaches. While most next-generation sequencing (NGS) solutions rely on DNA as input, RNA sequencing provides unique molecular insights that can inform decision making, particularly from detecting gene fusions, exon skipping, and changes in gene expression. However, practical barriers such as limited tissue availability, complex workflows, and time-consuming interpretation can challenge laboratories implementing RNA sequencing.
In this webinar, Alexandre Harlé, professor and hospital practitioner, will provide an in-depth look at expertly designed RNA NGS solutions for advanced variant detection from solid tumors, including lung and sarcoma. Harlé will share his experience of co-developing and implementing in-house, sample-to-report solutions that address the current and future needs of the Cancer Institute of Lorraine in Nancy, France.
Learning objectives:
Discover the robust analytical performance of an innovative RNA technology that detects novel (partner-agnostic) gene fusions — even when fusion partners are unknown — as well as exon skipping events and gene expression changes from small input amounts. Explore how decentralized sample-to-report workflows with fully integrated analysis, interpretation, and reporting features help accelerate turnaround times and improve operational efficiency.
Understand the value of combining targeted RNA and DNA insights to capture a more comprehensive molecular picture to support informed decision-making.
Speaker Bio:
Professor Alexandre Harlé leads the Precision Medicine and Translational Research group at the Institut de Cancérologie de Lorraine (ICL), France. His research focuses on integrating RNA sequencing and liquid biopsy approaches to better understand tumor biology and improve patient care. He has contributed to collaborative efforts developing RNA-based signatures, such as GemPred, for predicting chemotherapy response in pancreatic cancer. His team is also involved in national studies exploring circulating tumor DNA (ctDNA) for minimal residual disease detection and longitudinal monitoring. Combining clinical expertise with advanced molecular techniques, Harlé’s work aims to support the implementation of precision oncology in routine practice.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
